Follow-up study to evaluate sustained clearance rates of actinic keratoses up to one year after completion of studies GW01-0702, GW01-0703, GW01-0704, and GW01-0705.
Phase of Trial: Phase III
Latest Information Update: 19 Jul 2010
At a glance
- Drugs Imiquimod (Primary)
- Indications Actinic keratosis
- Focus Therapeutic Use
- Sponsors Graceway Pharmaceuticals
- 29 Jan 2010 Actual end date (Jul 2009) added as reported by ClinicalTrials.gov.
- 29 Jan 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 21 May 2008 New trial record.